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Abstract
5-HT1A and 5-HT7 receptors have been at the center of discussions recently due in part to their 
major role in the etiology of major central nervous system diseases such as depression, sleep 
disorders, and schizophrenia. As part of our search to identify dual targeting ligands for these 
receptors, we have carried out a systematic modification of a selective 5HT7 receptor ligand 
culminating in the identification of several dual 5-HT1A and 5-HT7 receptor ligands. Compound 
16, a butyrophenone derivative of tetrahydroisoquinoline (THIQ), was identified as the most 
potent agent with low nanomolar binding affinities to both receptors. Interestingly, compound 16 
also displayed moderate affinity to other clinically relevant dopamine receptors. Thus, it is 
anticipated that compound 16 may serve as a lead for further exploitation in our quest to identify 
new ligands with the potential to treat diseases of CNS origin.
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1. Introduction
It is now well established that targeting a single receptor is often inadequate in treating 
several diseases including diseases originating from the central nervous system. Thus, drugs 
such as aripiprazole, lurasidone and others derive their superior therapeutic outcomes from 
their ability to target multiple receptors in the CNS.1–4
The neurotransmitters, dopamine (DA) and serotonin (5-HT), are of particular interest 
because of their involvement in several neurological and psychiatric diseases such as 
schizophrenia, major depressive disorder (MDD), depression, attention deficit and 
hyperactivity disorder (ADHD), and addiction.5–8 Recent research has indicated that the 
serotonin receptors (5-HTRs) in particular play significant roles in CNS physiological 
activities, and dysregulation of these receptors often results in several diseases. For example, 
the serotonin 1A receptor (5-HT1AR) which is found predominantly in the dorsal raphe 
nuclei, hippocampus, and cortico-limbic regions, controls memory, cognition, and mood, 
functions which are impaired in anxiety, depression and schizophrenia.9 Several lines of 
evidence now support the anti-negative symptoms and cognitive enhancement effects of 
ligands which activate 5-HT1AR in schizophrenia.6,10 Similarly, the serotonin 7 receptor (5-
HT7R), the most recent addition to the 5-HT receptor subtypes,11–13 has been shown to 
mediate key functions such as sleep, mood, learning, memory, and cognition.14–17 
Interestingly, the 5-HT7R forms heterodimers with the 5-HT1AR in most brain regions, 
producing a cross talk which has been implicated in depression and other CNS disorders. 
Both receptors share over 40% sequence homology which may account for the cross 
reactivity seen among ligands which interact at both receptors.18–20 It stands to reason 
therefore that agents with dual binding affinities to both receptors may be beneficial as 
treatment options for depression and other cognitive impairment disorders.
Our lab has been engaged in multiple receptor-targeting in order to extend the scope and 
utility of CNS agents. The purpose of the current research was to investigate the 1,2,3,4-
tetrahydroisoquinoline (THIQ) moiety as a pharmacophore for the dual targeting of the 5-
HT1A and 5-HT7 receptors so as to probe their potential utility in CNS diseases. To that end, 
we have designed and synthesized several arylalkyl substituted THIQs in order to identify 
new lead agents for further development.
2. Chemistry
In general, the compounds evaluated in this manuscript were obtained by refluxing or 
carrying out a microwave-assisted reaction of THIQ with various alkylating agents in 
dimethoxyethane (DME) or acetonitrile (CH3CN) in the presence of K2CO3 as a base and a 
catalytic amount of KI. The target compounds were prepared by first N-alkylating potassium 
phthalimide with 1,4-dibromobutane to produce alkyl bromide 1b which was separately 
reacted with THIQ, decahydroisoquinoline, and isoindoline to afford compounds 1, 2 and 3 
respectively (Scheme 1). A three-step reaction procedure was used to synthesize compound 
4 (Scheme 2). Commercially available 4-(1H-indol-3-yl)butanoic acid, 2a was reduced using 
LAH in dry THF to produce the corresponding alcohol which was subsequently converted to 
the iodo intermediate 2b via an Appel reaction.21,22 The obtained alkylating agent was then 
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coupled to THIQ to afford 4. Deoxygenation of the previously reported indanone 3a23 under 
Clemmenson reduction conditions yielded 3b which was then used to alkylate THIQ and 
afforded compound 5 as shown in Scheme 3. Chloride 4a, mesylate 4b, and tosylate 4c were 
synthesized by literature procedures and subsequently used to alkylate THIQ to yield 
compounds 6, 7, and 8 respectively (Scheme 4) using the general alkylating conditions 
described in Scheme 1. Sulfoxide 9 was prepared by oxidation of 8 using the previously 
reported meta peroxybenzoic acid (m-CPBA) mediated oxidative conditions depicted in 
Scheme 5.23
Alkylating agents 6a, 6b, and 6e were obtained commercially and were used to synthesize 
compounds 10, 11, and 16 respectively whereas 6c and 6d were prepared following Friedel-
Crafts acylation reaction as reported24 and subsequently used to obtain compounds 12a and 
14 respectively (Scheme 6). Finally, using potassium ferrocyanide (K4[Fe(CN)6].3H2O) as 
the cyanide source, palladium catalyzed cyanation25 of 12a afforded compound 12 (Scheme 
6). Base-catalyzed hydrolysis of the cyano group26 in 12 afforded the corresponding amide 
13 (Scheme 6). Demethylation of 14 with hydrobromic acid afforded compound 15 (Scheme 
6).
3. Results and Discussion
The THIQ moiety has been the subject of several recent publications.27–33 In a campaign to 
synthesize new drugs with selective affinity for the 5-HT7 receptor, we synthesized 2-(4-
(3,4-dihydroisoquinolin-2(1H)-yl)butyl)isoindoline-1,3-dione (1) and evaluated its affinity 
for key 5-HTR subtypes including the 5-HT7R. As shown in Table 1, compound 1 
demonstrated a low nanomolar potency at the 5-HT7R and little affinity to the other key 5-
HTR subtypes including 5-HT1AR where it is over 50-fold less potent. Replacement of the 
THIQ ring in 1 with decahydroisoquinoline to yield 2 resulted in close to a 40-fold decrease 
in binding affinity to the 5-HT7R, with binding affinity at 5-HT1AR and 5-HT2AR remaining 
essentially unchanged. Compound 2 however, displays selectivity towards the 5-HT2CR (Ki 
= 37 nM). Further modification of 1 by replacing the tetrahydroisoquinoline ring with 
isoindoline ring to obtain 3 resulted in significant loss of activity at all receptor subtypes 
except the 5-HT2CR where there was moderate affinity (Ki = 151 nM). Based on the results 
of the binding affinities for compounds 1 – 3, it is clear that the THIQ ring serves as an 
important pharmacophore for binding affinity to the 5-HT7R in these compounds. This 
observation informed the next design strategy to keep the THIQ group and to focus on 
modifications elsewhere in the molecule, including that of the isoindoline-1,3-dione moiety.
Replacement of the isoindoline-1,3-dione moiety in 3 with indole to obtain 4 restored 
nanomolar binding affinity to the 5-HT7R, while replacement with 5-fluoro-2,3-dihydro-1H-
indene to form 5, led to significant binding affinity to both 5-HT1AR and 5-HT7R (Ki = 193 
and 86 nM respectively). Excision of a methylene group from the indene moiety in 
compound 5 led to ring-opened 6 with improved affinity for both 5-HT1AR and 5-HT7R. 
Replacement of the benzylic methylene group in 6 with oxygen (7) and sulfur (8) did not 
result in significant changes. However, oxidation of the sulfide to obtain the sulfoxide 9, 
increased affinity for both 5-HT1AR (Ki = 41 nM) and 5-HT7R (Ki = 22.5 nM).
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Next, the sulfoxide group in 9 was replaced by a carbonyl to form 4-(3,4-
dihydroisoquinolin-2(1H)-yl)-1-(4-fluorophenyl)butan-1-one (10) which resulted in a 3-fold 
increase in binding affinity at the HT1AR (Ki = 12 nM) but a decrease of 16-fold at the 5-
HT7R (Ki = 364 nM). Interestingly, affinity at the 5-HT2AR is found to have improved 
drastically to 14 nM. Similar low nanomolar binding affinities are observed for compounds 
11 (the defluorinated analog) and 12 (replacement of the fluoro with the electron 
withdrawing and hydrophilic cyano substituent) at the 5-HT2AR while significant loss of 
affinities are noted at the 5-HT1AR and 5-HT7R. However, changing the p-cyano substituent 
in 12 to the carboxamide 13, the methoxy group 14, or its hydroxy analog 15, produced the 
desired dual 5-HT1AR and 5-HT7R binding affinity ligands with low nanomolar affinity 
constants. Thus, it would appear that various substituents covering at least three quadrants of 
the Craig plot did not yield a clearly defined structure affinity relationship trend. Finally, we 
evaluated compound 16, with the p-fluoro atom of compound 10 replaced by a chloro atom 
which yielded the most potent dual 5-HT1AR (Ki = 8.2 nM) and 5-HT7R (Ki = 3.6 nM) 
binding affinity ligand in the series. Comparing compound 16 and Aripiprazole, both have 
high affinities at 5-HT1AR (5.6 vrs. 8.2 nM), and 5-HT7R (3.6 vrs. 10.3 nM), but differ 
significantly at the other serotonin receptors evaluated, with compound 16 having little or no 
binding at 5-HT2AR and 5-HT2CR (Ki = 2976 nM) and moderate binding at 5-HT2BR (Ki = 
232 nM), while Aripiprazole has high affinity for 5-HT2AR (Ki = 8.7 nM) and 5-HT2BR (Ki 
= 0.36 nM) and moderate affinity to 5-HT2CR (Ki = 76 nM).
The target compounds were also screened at additional CNS receptors with clinical 
significance including the D2R, D3R, D4R, H1R and SERT and the results reported in Table 
2. Compounds 1 – 3 showed little if any affinities at the aforementioned receptors/
transporter. Compound 4, the indolealkyl substituted analog of 1, produced moderate 
affinities for D2R, D4R and SERT while the dihydroindene analog 5 had moderate affinities 
for D3R, D4R and SERT. Opening the dihydroindene ring in 5 with excision of a methylene 
group (6), or replacing the benzylic carbon with oxygen, sulfur, or sulfoxide (7-9) resulted in 
significant loss of affinity for SERT with no clear SAR features at the other receptors in 
Table 2. Replacement of the sulfoxide with a carbonyl (10) produced significant increase in 
binding at the dopamine receptors, suggesting that perhaps the butyrophenone THIQ 
scaffold could constitute a useful hit for further development as ligands for multiple receptor 
targeting. However, probing the electron donating or withdrawing nature and/or the 
hydrophilic/hydrophobic nature of substituents at the para position of the phenyl ring (10 
-16) according to the Craig plot procedure34 did not produce an increase in potency at the 
dopamine receptors and did not reveal any interesting SAR trend. Regarding their histamine 
binding affinities, only 10 and 11 have affinity constants below 100 nM suggesting that these 
compounds may have low propensity for interacting at the histamine H1 receptor and hence 
less sedative effect.
Of the sixteen compounds reported, three, compounds 13, 14 and 16 (13: Ki = 13 nM, 14: Ki 
= 38 nM, 16: Ki = 17 nM respectively) show significant binding affinities to the D3R. Given 
their concentration in limbic and cortical regions of the brain, D3Rs have been hypothesized 
to be potential targets for the design of new antipsychotics with limited extrapyramidal side 
effects. However, there have been reports that selective D3R blockade only resulted in 
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marginal antipsychotic effects. This has led to the suggestion and indeed demonstration that 
dual D2/D3 receptor blockade produce effective antipsychotic actions.35–37
The moderate binding affinities of these compounds for the D2 receptors (13: Ki = 218 nM, 
14: Ki = 249 nM, 16 Ki = 126 nM), combined with their serotonin binding profiles make 
them potential drug leads for further exploitation. In particular, the preferential and more 
potent binding of 16 at D3R (Ki = 17 nM) compared to D2R (7 fold) suggest further 
evaluation for intrinsic activities and subsequent exploitation in the treatment of CNS 
conditions including the negative and cognitive symptoms of schizophrenia and bipolar 
mania.38–40 Interestingly, the D3R binding of compound 16 is similar to that of aripiprazole 
(Ki = 17 vrs. 9.7 nM), while the D2R binding affinity is similar to that of clozapine41 (Ki = 
126 nM vrs. pKi = 6.87 or Ki = 130 nM). Strong binding to the D3R may also be associated 
with procognitive effects, as reported.42
In conclusion, using compound 1 which showed significant selectivity (>50 fold) for 5-HT7 
receptor compared to the 5-HT1AR as our starting hit, and guided by results from our SAR 
studies, we were able to obtain very potent dual 5-HT1A and 5-HT7 receptor affinity ligands. 
In addition, compound 16 showed moderate binding affinity at D2R, high affinity at D3R, 
and a 7-fold selectivity for D3R over D2R, which portends a lead with great potential for 
further development in treating the negative and cognitive symptoms of schizophrenia, as 
well as bipolar mania. We opine that butyrophenone derivatives of THIQ such as 16 could 
serve as important leads to exploit for more potent CNS drugs with multi-receptor affinity 
features.
4. EXPERIMENTAL
Melting points were determined on a Gallenkamp (UK) apparatus and are uncorrected. All 
NMR spectra were obtained on a Varian 300 MHz Mercury Spectrometer and the free 
induction decay (FID) data were processed using Mestrelab’s Mnova NMR software 
(version 8.1) to obtain the reported NMR data. Elemental analyses were carried out by 
Atlantic Microlab, Inc., Norcross, GA, and are within 0.4% of theory unless otherwise 
noted. Flash chromatography was performed using CombiFlash® with Davisil grade 634 
silica gel. Starting materials were obtained from Sigma–Aldrich and were used without 
further purification. All microwave assisted syntheses (MW) were carried out using a 
Biotage Initiator®.
4.1. Synthesis of 2-(4-Bromobutyl)isoindoline-1,3-dione, 1b
A mixture of potassium phthalimide 1a (0.93 g, 5 mmol) and 1,4-dibromobutane (5.4 g, 25 
mmol) was stirred in dry DMF (10 mL) at 100 °C for 12 h. The condenser was then set for 
distillation, and the excess of 1,4-dibromobutane and DMF was removed under reduced 
pressure. The crude product obtained was purified by column chromatography (silica gel, 
ethyl acetate/light petroleum 1:50) to afford intermediate 1b as a colorless solid. 1H NMR 
(CDCl3): δ 7.87-7.84 (2H, m), 7.74-7.71 (2H, m), 3.73 (2H, t, J = 6.9 Hz), 3.45 (2H, t, J = 
6.3 Hz), 1.90-1.88 (4H, m).
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4.2. General alkylation procedure for compounds 1-3
A mixture of 1b (1 equiv), an appropriate amine (1.2 equiv), KI (100 mg), and K2CO3 (10 
equiv), in CH3CN (15 mL) or DME was refluxed for 12–24 h. The reaction progress was 
monitored by TLC and at completion, the mixture was cooled to room temperature, solvent 
removed, the resulting residue loaded onto a cartridge and purified by flash chromatography 
using an EtOAc/hexane gradient up to 80% EtOAc) to give the pure desired products.
4.2.1. 2-(4-(3,4-Dihydroisoquinolin-2(1H)-yl)butyl)isoindoline-1,3-dione, 1—
Following the general alkylation procedure described in section 4.2 and using THIQ as the 
amine, compound 1 was obtained as the free base. Yield: 22%, mp: 68–69 °C. 1H NMR 
(DMSO-d6): δ 7.86-7.79 (4H, m), 7.07-6.98 (4H, m), 3.58 (2H, t, J = 6.9 Hz), 3.47 (2H, s), 
2.75 (2H, t, J = 5.4 Hz), 2.58 (2H, t, J = 6.0 Hz), 2.43 (2H, t, J = 6.9 Hz), 1.68-1.48 (4H, m). 
Calcd for C21H22N2O2·0.2H2O; C 74.62, H 6.68, N 8.29; Found: C 74.55, H 6.55, N 8.25.
4.2.2. 2-(4-(Octahydroisoquinolin-2(1H)-yl)butyl)isoindoline-1,3-dione, 2—Using 
decahydroisoquinoline as the amine, compound 2 was prepared similarly to 1 above. Yield: 
12%, mp: 64–65°C. 1H NMR (CDCl3): δ 7.84-7.82 (2H, dd, J = 3.0, 8.7 Hz), 7.70 (2H, dd, 
J = 3.0, 9.0 Hz), 3.70 (2H, t, J = 7.2 Hz), 2.91 (1H, d, J = 8.1 Hz), 2.75 (1H, d, J = 9.0 Hz), 
2.31 (2H, s), 1.77 (1H, t, J = 7.2 Hz), 1.71-1.48 (1H, m), 1.26-1.19 (4H, m), 0.98-0.87 (2H, 
m). Calcd for C21H28N2O2; C 74.08, H 8.29, N 8.23; Found: C; 73.82, H; 8.09, N; 8.19.
4.2.3. 2-(4-(Isoindolin-2-yl)butyl)isoindoline-1,3-dione, 3—Following the general 
alkylation procedure in section 4.2 and using isoindoline as the amine, compound 3 was 
obtained as the free base. Yield: 21%, mp: 95–96°C. 1H NMR (DMSO-d6): δ 7.88-7.78 (m, 
4H), 7.20-7.12 (m, 4H), 3.76 (s, 4H), 3.59 (t, 2H, J = 5.7 Hz), 2.63 (t, 2H, J = 7.2 Hz), 
1.70-1.44 (m, 4H). Calcd for C20H20N2O2·0.11 H2O; C 72.78, H 6.11, N 8.49; Found: C 
72.75, H 6.16, N 8.12.
4.3. Synthesis of 3-(4-iodobutyl)-1H-indole, 2b
To a solution of indole-3-butyric acid 2a (2 g, 9.8 mmol) dissolved in dry THF (30 mL) and 
cooled to 0 °C was added portionwise LiAlH4 (2.2 g, 59 mmol, 6 eq) in dry THF. The 
mixture was allowed to warm to room temperature (rt) with stirring for 18h. The reaction 
mixture was cooled to 0 °C and a saturated solution of Na2SO4 (20 mL) was added in a 
dropwise manner over the period of 30 min. The resulting white precipitate was filtered, the 
filtrate washed with EtOAc (2 × 100 mL), the pooled organic phase washed with water (50 
mL) and saturated brine solution (50 mL), dried over anhydrous Na2SO4 and the solvent 
removed under reduced pressure to obtain the crude product. The crude 3-(4-
hydroxybutyl)-1H-indole was used for the next step without further purification.
The crude obtained was converted to compound 2b following a procedure reported in 
literature.21 Briefly, to a stirred solution of PPh3 (4.46 g, 17.0 mmol) and imidazole (1.58 g, 
17.0 mmol) in DCM (45 mL) at 0 °C, was added I2 (4.32 g, 17.0 mmol) and the reaction 
mixture was stirred at this temperature for 30 min. Thereafter, a solution of crude 3-(4-
hydroxybutyl)-1H-indole (2.30 g, 12.2 mmol) in DCM (5 mL) was added, the reaction 
mixture was allowed to warm to rt and stirred for 12 h. The crude product was directly 
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purified using silica gel on CombiFlash with gradient up to 40% EtOAc in hexanes to afford 
compound 2b (2.40 g) as an oily liquid. Yield: 66%. 1H NMR (CDCl3): δ 7.91 (1H, s). 7.59 
(1H, d, J = 8.1Hz), 7.35 (1H, d, J = 8.1 Hz), 7.22-/7.17 (1H, t, J = 6.9 Hz), 7.12 (1H, m), 
6.97 (1H, d, J = 2.1 Hz), 3.22 (2H, t, J = 6.9 Hz), 2.84 (2H, t, J = 6.9 Hz), 1.96-1.76 (4H, m).
4.4. 2-(4-(1H-indol-3-yl)butyl)-1,2,3,4-tetrahydroisoquinoline, 4
Following the general alkylation procedure described above (section 4.2.) and using the 
obtained 2b as the alkylating agent, compound 4 was obtained. Yield: 52%, mp: 139–
140 °C. 1H NMR (CDCl3): δ 7.96 (1H, s), 7.62-7.60 (1H, d, J = 8.4 Hz), 7.35 (1H, d, J = 7.8 
Hz), 7.21-7.15 (1H, m), 7.13-7.07 (4H, m), 7.01-6.98 (2H, m), 2.90 (2H, t, J = 5.7 Hz), 2.81 
(2H, t, J = 6.9 Hz), 2.73 (2H, t, J = 6.0 Hz), 2.56 (2H, t, J = 7.2 Hz), 1.80-1.69 (6H, m,). 
Calcd for C21H24N2; C 82.85, H 7.97, N 9.20; Found: C 82.65, H 7.97, N 8.97.
4.5. Synthesis of 2-(2-chloroethyl)-5-fluoro-2,3-dihydro-1H-indene, 3b
Amalgamated zinc was prepared by stirring a mixture of zinc (1.2 g), HgCl2 (0.12 g) in 5 
mL water with conc. HCl (0.1 mL) at room temperature. After stirring for 5 min, the mixture 
was decanted and followed by adding in order water (1 mL), conc HCl (1.75 mL), toluene 
(10 mL), and then 2-(2-Chloro-ethyl)-5-fluoro-indan-1-one 3a (2 g, 9.43 mmol), synthesis of 
which was previously reported by us.23 The mixture was refluxed with stirring for 12 h. The 
solid was filtered off, aqueous layer was diluted with EtOAc (200 mL), washed with water, 
and then saturated NaHCO3 (50 mL). The organic layer was dried over Na2SO4, and filtered. 
The filtrate was concentrated in vacuo followed by column chromatography on silica gel to 
afford 3b, 1.68 g, Yield 90%. 1H NMR (CDCl3): δ 7.09 (1H, dd, J = 4.8, 7.8 Hz), 6.85 (2H, 
m), 3.60 (2H, t, J = 7.2 Hz), 3.04 (2H, m), 2.70 (1H, m), 2.56 (2H, m), 1.98 (2H, m).
4.6. 2-(2-(5-Fluoro-2,3-dihydro-1H-inden-2-yl)ethyl)-1,2,3,4-tetrahydroisoquinoline 
hydrochloride, 5
Alkylating agent 3b was reacted with THIQ following the general alkylation procedure 
described in section 4.2 to obtain compound 5 as its HCl salt. Yield: 42%, mp: 211–
212 °C. 1H NMR (DMSO-d6): 10.85 (1H, s), 7.19 (5H, m), 7.02 (1H, d, J = 9.0 Hz), 6.92 
(1H, t, J = 9.0 Hz), 4.51 (1H, m), 4.27 (1H, m), 3.67 (1H, m), 3.40 (1H, m), 3.23 (4H, m), 
3.02 (4H, m), 2.60 (1H, m), 1.98 (2H, m). Calcd for C20H23ClFN: C 72.00, H 6.95, N 4.20; 
Found: C 71.89, H 6.97, N 4.28.
4.7. General alkylation procedure for compounds 6-8, 10-12a, 14, and 16
A mixture of alkylating agent (1 equiv), THIQ (1.1 equiv) K2CO3 (1.1 equiv), and KI 
(catalytic) in DME (10 mL) was placed in a 20 mL microwave vial with a stirrer and tightly 
sealed. The mixture was subjected to microwave heating at 120°C for 60 mins. The mixture 
was directly purified on silica by flash chromatography (gradient up to 70% EtOAc in 
hexanes) to afford compound 7. The free base where necessary, was converted to the HCl 
salt and crystallized out of a MeOH-Et2O solvent mixture.
4.7.1. 2-(4-(4-Fluorophenyl)butyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride, 
6—The synthesis of 1-(4-chlorobutyl)-4-fluorobenzene 4a was previously reported by us23 
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and following the procedure described in section 4.7., 4a was reacted with THIQ to afford 
compound 6 as its HCl salt form. Yield: 75%, mp: 205–206 °C. 1H NMR (DMSO-d6): δ 
7.30-7.06 (6H, m); 6.99-6.92 (2H, m); 4.60-4.55 (1H, m); 4.01-3.94 (1H, m), 3.65-3.59 (1H, 
m), 3.51-3.42 (1H, m), 3.27-3.17 (1H, m), 3.07-2.93 (4H, m), 2.66 (2H, t, J = 7.5); 2.08-1.96 
(2H, m), 1.75-1.63 (2H, m). Calcd for C19H23ClFN·0.2H2O: C 70.55, H 7.17, N 4.33; 
Found: C 70.73, H 7.36, N 4.45.
4.7.2. 2-(3-(4-Fluorophenoxy)propyl)-1,2,3,4-tetrahydroisoquinoline 
hydrochloride, 7—Following the general alkylation procedure described above (section 
4.7.), previously reported alkylating agent 3-(4-fluorophenoxy)propyl methanesulfonate 
4b23 was reacted with THIQ to give compound 7 as a white crystalline HCl salt. Yield: 30%, 
mp: 196–197 °C. 1H NMR (DMSO-d6): δ 11.23 (1H, brs), 7.25 (4H, m), 7.15 (2H, m), 6.95 
(2H, m), 4,54 (1H, d, J = 15.6 Hz), 4.28 (1H, dd, J = 8.4, 15.6 Hz), 4.06 (2H, t, J = 6.0 Hz), 
3.69 (1H, m), 3.24 (2H, m), 3.34 (2H, m), 3.00 (1H, m), 2.28 (2H, m). Calcd for 
C18H21ClFNO: C 67.18, H 6.58, N 4.35; Found: C 67.10, H 6.55, N 4.38.
4.7.3. 3-((4-Fluorophenyl)thio)propyl 4-methylbenzenesulfonate, 4c—To a 
solution of 3-(4-fluorophenylthio)propan-1-ol23 (1 g, 5.4 mmol), Et3N (2 mL) in CH2Cl2 (10 
mL) was added at room temperature TsCl (1.54 g, 8.1 mmol). The mixture was stirred at 
room temperature for 12 h, followed by direct purification using column chromatography on 
silica gel to provide 4c, 1.72 g, Yield 94%. 1H NMR (CDCl3): δ 7.77 (2H, J = 8.4 Hz), 7.34 
(2H, J = 8.4 Hz), 7.30 (2H, dd, J = 5.4, 8.4 Hz), 6.97 (2H, J = 8.7 Hz), 4.13 (2H, t, J = 8.0 
Hz), 2.86 (2H, J = 7.2 Hz), 1.89 (2H, m).
4.7.4. 2-(3-((4-Fluorophenyl)thio)propyl)-1,2,3,4-tetrahydroisoquinoline 
hydrochloride, 8—Reacting alkylating agent 4c and THIQ under the general alkylation 
conditions (section 4.7.) produced compound 8 as an HCl salt. Yield: 29%, mp: 172–
173 °C. 1H NMR (DMSO-d6): δ 11.31 (1H, m), 7.44 (2H, m), 7.22 (6H, m), 4.46 (1H, d, J 
= 15.3 Hz), 4.22 (1H, dd, J = 7.5, 15.3 Hz), 3.61 (1H, m), 3.27 (4H, m), 3.04 (2H, t, J = 6.0 
Hz), 2.95 (1H, m), 2.08 (2H, m). Calcd for C18H21ClFNS: C 63.98, H 6.26, N 4.15; Found: 
C 63.77, H 6.27, N 4.18.
4.7.5. 2-(3-((4-Fluorophenyl)sulfinyl)propyl)-1,2,3,4-tetrahydroisoquinoline 
hydrochloride, 9—To a solution of 8 (0.2g, 0.59 mmol) in MeOH (5 mL) was added with 
stirring m-CPBA (0.2 g) at 0 °C. After stirring for 1 h. at room temperature, the mixture was 
diluted with Et2O (10 mL). A solid precipitate was collected by filtration. Further 
crystallization from MeOH-Et2O gave 0.15g of 9 as an HCl salt. 73% Yield: 73%, mp: 177–
178 °C. 1H NMR (DMSO-d6): δ 10.53 (1H, brs), 7.74 (2H, dd, J = 4.8, 8.4 Hz), 7.45 (2H, t, 
J = 8.7 Hz), 7.22 (4H, m), 4.50 (1H, d, J = 15.3 Hz), 4.25 (1H, dd, J = 7.5, 15.3 Hz), 3.63 
(1H, m), 3.27 (3H, m), 3.14 (2H, m), 3.98 (1H, m), 2.88 (1H, m), 2.15 (1H, m), 2.00 (1H, 
m). Calcd for C18H21ClFNOS·0.3H2O: C 60.17, H 5.89, N 3.90; Found: C 60.09, H 5.82, H 
3.94.
4.7.6. 4-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-(4-fluorophenyl)butan-1-one, 10—
Using 4-chloro-1-(4-fluorophenyl)butan-1-one 6a as the alkylating agent, compound 10 was 
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obtained as a white solid (free base) following the general alkylation method (section 4.7.). 
Yield: 38%, mp: 104–105 °C. 1H NMR (CDCl3): 7.96 (2H, dd, J = 5.4, 9.0 Hz), 6.98–7.11 
(6H, m), 3.61 (2H, m), 3.03 (2H, t, J = 7.2 Hz), 2.86 (2H, t, J = 6.0 Hz), 2.72 (2H, t, J = 6.0 
Hz), 2.58 (2H, t, J = 6.9 Hz), 2.03 (2H, q, J = 6.9 Hz). Calcd for C19H20FNO: C 76.74, H 
6.78, N 4.71; Found: C 76.51, H 6.83, N 4.69.
4.7.7. 4-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-phenylbutan-1-one, 11—Following 
the general alkylation procedure (section 4.7.), 4-chloro-1-phenylbutan-1-one 6b was 
reacted with THIQ to produce compound 11 as its HCl salt to afford a white crystalline solid 
(1.2g). Yield: 69%, mp: 185–187 °C. 1H NMR (DMSO-d6) δ 11.39 (s, 1H), 7.98 (2H, d, J = 
7.6 Hz), 7.63 (1H, d, J = 7.3 Hz), 7.53 (2H, dd, J = 7.5 Hz), 7.28 - 7.17 (4H, m), 4.53 (1H, 
dd, J = 3.1, 15.4 Hz), 4.27 (1H, dd, J = 7.7, 15.6 Hz), 3.68 (1H, s), 3.35 - 3.17 (6H, m), 2.98 
(1H, dd, J = 3.3, 12.6 Hz), 2.24 - 2.07 (2H, m). 13C NMR (75 MHz, DMSO-d6) δ 199.18, 
136.82, 133.77, 131.96, 129.19, 129.01, 128.95, 128.36, 127.95, 127.09, 127.00, 54.97, 
51.91, 48.93, 35.68, 25.19, 18.40. Calcd for C19H22ClNO: C 72.25, H 7.02, N 4.43; Found: 
C 71.97, H 7.01, N 4.30.
4.7.8. 1-(4-Bromophenyl)-4-(3,4-dihydroisoquinolin-2(1H)-yl)butan-1-one 
hydrochloride, 12a—Following the procedure in section 4.7., the alkylating agent 1-(4-
bromophenyl)-4-chlorobutan-1-one 6c was reacted with THIQ to obtain 12a as its HCl salt. 
Yield: 54%, mp: 211–212°C. 1H NMR (DMSO-d6) δ 11.44 (1H, s), 7.90 (2H, dd, J = 8.5, 
1.9 Hz), 7.73 (2H, dd, J = 8.5, 1.9 Hz), 7.29 - 7.16 (4H, m), 4.51 (1H, d, J = 15.5 Hz), 
4.34-4.19 (1H, m), 3.69 - 3.62 (1H, m), 3.36 - 3.19 (6H, m), 2.97 (1H, d, J = 13.1 Hz), 2.13 
(2H, q, J = 7.5 Hz). 13C NMR (75 MHz, DMSO-d6) δ 198.43, 135.84, 132.23, 131.96, 
130.38, 128.99, 128.93, 127.94, 127.81, 127.07, 126.99, 54.90, 51.90, 48.92, 35.74, 25.17, 
18.32. Calcd for C19H21BrClNO: C 57.81, H 5.36, N 3.55; Found: C 57.67, H 5.29, N 3.65.
4.8. 4-(4-(3,4-Dihydroisoquinolin-2(1H)-yl)butanoyl)benzonitrile, 12
To a 25 mL flask equipped with a stirrer was added 12a (0.79 g, 2.6 mmol) in its free base 
form, dimethylacetamide (DMAC) (15 mL), K4[Fe(CN)6].3H2O (0.93 g, 2.2 mmol), 
Na2CO3 (0.23 g, 2.2 mmol), KI (73.0 mg, 20 mol%), and Pd(OAc)2 (0.4 mol%). The flask 
was evacuated and filled with N2 and heated to 120 °C for 12 hours. Reaction conversion 
was monitored by TLC. Upon completion, the reaction mixture was cooled to rt, 5% 
NH4OH (20 mL) was added, extracted with 20 mL x 3 of EtOAc, the pooled organic layers 
was washed with brine (20 mL), dried over Na2SO4 and the filtrate was concentrated in-
vacuo. The crude was purified on silica by flash chromatography (Hexanes: EtOAc gradient 
up to 80% EtOAc) to afford 12 which was converted to the HCl salt (0.508 g) as white 
crystals. Yield: 68%, mp: 199–200 °C. 1H NMR (DMSO-d6) δ 11.11 (1H, s), 8.12 (2H, dd, 
J = 1.8, 8.5 Hz), 8.03 (2H, dd, J = 2.1, 8.5 Hz), 7.31-7.16 (4H, m,), 4.55 (1H, dd, J = 3.2, 
14.7 Hz), 4.28 (1H, dd, J = 7.7, 15.5 Hz), 3.70 (1H, d, J = 9.7 Hz), 3.36 - 3.21 (6H, m), 3.02 
(1H, d, J = 3.6 Hz), 2.15 (2H, q, J = 6.9, 7.9 Hz).13C NMR (75MHz, DMSO-d6) δ 198.70, 
140.17, 134.68, 134.28, 132.29, 128.58, 128.38,126.52, 126.13, 125.56, 118.10, 115.77, 
57.15, 55.93, 50.81, 36.51, 28.96, 22.03. Calcd for C20H21ClN2O: C 70.48; H 6.21; N 8.22. 
Found: C 70.30, H 6.36, N 8.15.
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4.9. 4-(4-(3,4-Dihydroisoquinolin-2(1H)-yl)butanoyl)benzamide, 13
A mixture of 12 (0.3 g, 1 mmol) and KOH (0.22 g, 4 mmol) in t-BuOH (10 mL) was 
refluxed for 12 h. The reaction was allowed to cool to room temperature and extracted with 
EtOAc (15 mLx2). The organic layers were pooled and washed with brine (20 mL), dried 
over Na2SO4, filtered, and the filtrate reduced in-vacuo. The crude was purified by flash 
chromatography (Hexanes: EtOAc gradient up to 80% EtOAc) to obtain 13 (0.40 g) as white 
crystals. Yield: 46%, mp: 177–178°C. 1H NMR (DMSO-d6) δ 8.11 (1H, s), 7.97 (2H, dd, J 
= 2.5, 8.8 Hz), 7.92 (2H, dd, J = 2.5, 8.8 Hz), 7.54 (1H, s), 7.10 - 6.95 (4H, m), 3.48 (2H, s), 
3.06 (2H, t, J = 7.0 Hz), 2.71 (2H, t, J = 5.8 Hz), 2.59 (2H, t, J = 5.8 Hz), 2.48 (2H, t, J = 7.1 
Hz), 1.86 (2H, q, J = 7.1 Hz). 13C NMR (75 MHz, DMSO-d6) δ 200.07, 167.50, 139.17, 
138.25, 135.30, 134.61, 128.75, 128.17, 128.15, 126.80, 126.28, 125.80, 57.32, 55.86, 
50.85, 36.46, 29.06, 21.79. Calcd for C20H22N2O2: C, 74.51; H, 6.88; N, 8.69. Found: C, 
74.59; H, 6.70; N, 8.58.
4.10. 4-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-(4-methoxyphenyl)butan-1-one hydrochloride, 14
Following the alkylation procedure described in section 4.7. above and using 4-chloro-1-(4-
methoxyphenyl)butan-1-one 6d as the alkylating agent, compound 14 was obtained as the 
HCl salt. Yield: 60%, mp: 194–195°C. 1H NMR (DMSO-d6) δ 11.57 (1H, s), 7.97 (2H, dd, 
J = 2.1, 8.8 Hz), 7.31 - 7.19 (4H, m), 7.05 (2H, dd, J = 2.0, 8.7 Hz), 4.53 (1H, d, J = 15.5 
Hz), 4.29 (1H, d, J = 11.1 Hz), 3.84 (3H, s), 3.67 (1H, s), 3.35 - 3.11 (6H, m), 2.99 (1H, d, J 
= 12.7 Hz), 2.16 (2H, q, J = 7.9 Hz,).13CNMR (75 MHz, DMSO-d6) δ 197.55, 163.63, 
132.01, 130.69, 129.83, 129.03, 128.94, 127.95, 127.10, 127.00,114.35, 56.04, 55.06, 51.89, 
48.89, 35.32, 25.19, 18.56. Calcd for C20H24ClNO2: C 69.45, H 6.99, N 4.05. Found: C 
69.28; H 6.87, N 4.09.
4.11. 4-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-(4-hydroxyphenyl)butan-1-one hydrochloride, 15
To a dry microwave vial equipped with a stirrer and charged with NaI (0.17 g, 1.10 mmol) in 
HBr solution (48% aq., 10 mL) was added compound 14 in its free base form (0.31 g, 1.0 
mmol). The mixture was subjected to microwave heating at 110 °C for 30 mins. The reaction 
vial was allowed to cool to room temperature (rt) and the mixture directly purified using 
flash column chromatography (gradient elution up to 80% EtOAc in hexane). The product 
obtained was converted to its HCl salt to obtain compound 15 as a white flaky solid (0.21g). 
Yield: 63%, mp: 218–219°C. 1H NMR (DMSO-d6) δ 11.13 (1H, s), 10.51 (1H, s), 7.84 (2H, 
d, J = 8.0 Hz), 7.33 - 7.15 (4H, m), 6.87 (2H, d, J = 7.9 Hz), 4.48 (1H, s), 4.28 (1H, s), 3.66 
(1H, s), 3.35 - 2.93 (7H, m), 2.11 (2H, t, J = 7.8 Hz).13C NMR (75 MHz, DMSO-d6) δ 
197.24, 162.69, 131.95, 130.85, 128.94, 128.40, 127.98, 127.09, 127.01, 115.69, 55.20, 
52.14, 49.06, 35.00, 25.28, 18.74. Calcd. for C19H22ClNO2·0.75H2O; C 66.08, H 6.86, N 
4.06; Found: C 66.17, H 6.49, N 4.03.
4.12. 1-(4-Chlorophenyl)-4-(3,4-dihydroisoquinolin-2(1H)-yl)butan-1-one hydrochloride, 16
THIQ was alkylated with 4-chloro-1-(4-chlorophenyl)butan-1-one 6e and the product 
converted to its HCl salt to afford compound 16 as its HCl salt. Yield: 61%, mp: 209–
210 °C. 1H NMR (DMSO-d6): δ 11.00 (brs, 1H), 7.97 (2H, d, J = 9.0 Hz), 7.62 (2H, d, J = 
9.0 Hz), 7.27-7.18 (4H, m), 5.4 (1H, d, J = 14.4 Hz), 4.31-4.23 (1H, m), 3.74-3.64 (1H, m), 
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3.50-3.38 (2H, m), 3.36-3.25 (4H, m), 3.08-2.90 (1H, m), 2.17-2.10 (2H, m). 13C NMR (75 
MHz, DMSO-d6): δ 198.25, 138.62, 135.55, 131.96, 130.29, 129.29, 128.97, 128.94, 
127.97, 127.08, 127.08, 127.01, 54.93, 51.94, 48.95, 35.75, 25.17, 18.34. Calcd. 
C19H21Cl2NO; C 65.15, H 6.04, N 4.00; Found: C 65.03, H 6.16, N 3.99.
Receptor Binding studies
Binding affinities reported in Tables 1 and 2 were conducted by the National Institute of 
Mental Health Psychoactive Drug Screening Program (NIMH-PDSP) unless otherwise 
stated. Details of the methods and radioligands used for the binding assays were previously 
reported.3
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Scheme 1. 
Synthesis of isoindoline-1,3-dione analogs. Reagents and conditions: a) 1,4-dibromobutane, 
DMF, 100 °C; b) K2CO3/KI, CH3CN, reflux, 12–24 h. I = THIQ; ii = 
decahydroisoquinoline; iii = isoindoline.
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Scheme 2. 
Synthesis of 3-substituted-1H-indole analog. Reagents and condition: a) LiAlH4 in dry THF, 
rt,12 h; b) I2/PPh3, imidazole; c) THIQ, K2CO3/KI, DME, reflux,12 h.
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Scheme 3. 
Synthesis of 5-fluoro-2,3-dihydro-1H-indene analog. Reagents and conditions: a) Zn 
Amalgam, Conc. HCl, toluene, reflux; b) THIQ, K2CO3/KI, DME, reflux, 12 h; c) ethereal 
HCl.
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Scheme 4. 
Synthesis of 4-fluorobutyrophenone analogs. Reagents and conditions: a) THIQ, K2CO3/KI, 
DME, MW; b) ethereal HCl.
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Scheme 5. 
Synthesis of sulfoxide analog. Reagents and conditions: a) m-CPBA, MeOH, 0 °C to rt
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Scheme 6. 
Synthesis of 4-subtituted-butyrophenone analogs. Reagents and conditions: a. THIQ, 
K2CO3/KI, DME, 120 °C, MW; (b) K4[Fe(CN)6].3H2O, Pd(OAc)2, KI, Na2CO3, N 2, DMA, 
120 °C, 12 h; (c) KOH, t-butyl alcohol, reflux, 12 h; d) aq. HBr 48%, NaI, 110°C, MW.
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